Ponatinib-associated panniculitis: Case report and review of the literature

Ponatinib-associated panniculitis: Case report and review of the literature

Blog Article

Ponatinib is a tyrosine SELF DEFENSE kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphoblastic leukemia.Common adverse effects of ponatinib include neutropenia, arterial thrombosis, and hypertension.We describe a 49-year-old woman who developed panniculitis after brief treatment with ponatinib.In FOOT REFRESH addition, we summarize other studies describing TKI-associated panniculitis.